Fox Chase Cancer Center News

PHILADELPHIA (August 31, 2022)—Researchers at Fox Chase Cancer Center co-authored a multi-institutional study that found that an RNA modification enzyme is critical for the survival of motor neurons. The scientists say the findings could help in the development of new treatments for neurological and other aging-related disorders, including cancer.

PHILADELPHIA (August 30, 2022)—Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.

PHILADELPHIA (August 29, 2022)—In a recently published supplement, the American Cancer Society’s National Navigation Roundtable, which is co-chaired by a Fox Chase Cancer Center researcher, provided an extensive update on the state of patient navigation and its role in oncology care.

PHILADELPHIA (August 17, 2022)—Brian Kozera lived his life according to a very simple, yet powerful mantra: Persevere, prevail.  A dear member of our Fox Chase Cancer Center community, Brian was a cancer survivor (or cancer thriver, as he would say), fundraiser, and friend who inspired us with his resolve, his passionate spirit, and his selfless dedication to others. It is with deep sadness that I share news of his unexpected passing on August 13 in a biking accident. Brian was 44.

PHILADELPHIA (August 15, 2022)—Fox Chase Cancer Center is pleased to announce the hiring of Michael Scott, MD, who will be joining the Supportive Oncology and Palliative Care Program in the Department of Hematology/Oncology as an assistant professor.

PHILADELPHIA (August 9, 2022)—Fox Chase Cancer Center is pleased to announce the hiring of Austin D. Williams, MD, MSEd, as a surgeon in the Breast Cancer Program and an assistant professor in the Department of Surgical Oncology.

PHILADELPHIA (August 8, 2022)—Patients with metastatic small cell lung cancer (SCLC) have limited options for treatment, with few drugs available for patients who have already completed frontline chemotherapy and immunotherapy. Now a global multi-institutional study that included researchers from Fox Chase Cancer Center has shown that the investigational drug tarlatamab is a promising new potential treatment for SCLC.

PHILADELPHIA (August 4, 2022)—The Fels Cancer Institute for Personalized Medicine at the Lewis Katz School of Medicine at Temple University, in partnership with Fox Chase Cancer Center and Thomas Jefferson University, will host a free symposium, “Genome Instability: Discovery to Personalized Medicine.” This event will be held in person on Friday, October 14, 2022, at the DoubleTree by Hilton hotel in Philadelphia.